logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 20 of 34 Items
Showing 1 - 20 of 34 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research

An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART

Jelsma J, Maclean E, Hughes J, Tinise X, Darder M
2005-07-01 • AIDS Care
2005-07-01 • AIDS Care
The health authorities have recently accepted the routine provision of highly active antiretroviral therapy to persons living with AIDS in South Africa. There is a need to investigate th...
Journal Article
|
Short Report

Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?

Cox HS, Hughes J, Black JM, Nicol MP
2018-03-13 • Lancet Infectious Diseases
2018-03-13 • Lancet Infectious Diseases
Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...
Journal Article
|
Letter

Linezolid in drug-resistant tuberculosis: haste makes waste

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V,  et al.
2015-12-01 • European Respiratory Journal
2015-12-01 • European Respiratory Journal
Journal Article
|
Research

Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa

Cox HS, Hughes J, Daniels J, Azevedo VD, McDermid C,  et al.
2014-04-01 • International Journal of Tuberculosis and Lung Disease
2014-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.
Journal Article
|
Research

Time to ART initiation among patients treated for rifampin-resistant tuberculosis in Khayelitsha, South Africa: Impact on mortality and treatment success

Daniels J, Khogali MA, Mohr E, Cox V, Moyo S,  et al.
2015-11-10 • PLOS One
2015-11-10 • PLOS One
SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.

OBJECTIVE
To describe time to antiretroviral trea...
Journal Article
|
Research

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS,  et al.
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
Journal Article
|
Letter

Linezolid for multidrug-resistant tuberculosis

Cox HS, Ford NP, Hughes J, Goemaere E
2013-01-01 • Lancet Infectious Diseases
2013-01-01 • Lancet Infectious Diseases
Journal Article
|
Short Report

Challenges and controversies in childhood tuberculosis

Reuter A, Hughes J, Furin J
2019-09-14 • Lancet
2019-09-14 • Lancet
Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important...
Journal Article
|
Research

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F,  et al.
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|
Commentary

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Journal Article
|
Research

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF,  et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|
Research

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J,  et al.
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Journal Article
|
Research

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|
Letter

Critical changes to services for TB patients during the COVID-19 pandemic

Cox V, Wilkinson LS, Grimsrud A, Hughes J, Reuter A,  et al.
2020-04-02 • International Journal of Tuberculosis and Lung Disease
2020-04-02 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Research

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G,  et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Journal Article
|
Research

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting

Mohr E, Daniels J, Beko B, Isaakidis P, Cox V,  et al.
2017-05-18 • PLOS One
2017-05-18 • PLOS One
BACKGROUND
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Journal Article
|
Letter

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V,  et al.
2015-04-02 • European Respiratory Journal
2015-04-02 • European Respiratory Journal
Journal Article
|
Commentary

MDR tuberculosis and non-compliance with therapy

Cox HS, Hughes J, Ford NP, London L
2012-03-01 • Lancet Infectious Diseases
2012-03-01 • Lancet Infectious Diseases
Journal Article
|
Research

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N,  et al.
2015-07-19 • International Journal of Tuberculosis and Lung Disease
2015-07-19 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.

OBJECTIVE
To descri...